News

Correction: Orphazyme Announces Publication of 2021 Financial Results and Annual Report

Jun 8, 2022

Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), today reports its financial results for the period from January 1, 2021, to December 31, 2021, and publishes its Annual Report.

Correction Orphazyme Announces Publication of 2021 Financial Results and Annual Report

Annual Report 2021

Read more

Notice to convene Annual General Meeting

Jun 7, 2022

Orphazyme A/S (ORPHA.CO) (the “Company”), today announces the notice to convene the Company’s Annual General Meeting to be held on.

Appendix 1 Candidates for the Board of Directors 1

Notice to convene Annual General Meeting

Orphazyme Notice to convene AGM 2022

Read more

Orphazyme Announces Publication of 2021 Financial Results and Annual Report

Jun 7, 2022

Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), today reports its financial results for the period from January 1, 2021, to December 31, 2021, and publishes its Annual Report.

Annual Report 2021

Orphazyme Announces Publication of 2021 Financial Results and Annual Report

Read more

Orphazyme completes sale of substantially all of its assets and business activities to KemPharm

May 31, 2022

With reference to company announcement no. 24/2022 dated May 15, 2022, regarding the signing of an agreement to sell substantially all of the Orphazyme’s assets and business activities to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm Inc. (KMPH: NASDAQ, NY), (“KemPharm”), and company announcement no. 28/2022 dated May 30, 2022, regarding the approval of the restructuring proposal, Orphazyme A/S (ORPH) (“Orphazyme” or the “Company”), today announces that it has completed the sale of substantially all of its assets and business activities for a cash consideration of USD 12.8 million and assumption of liabilities estimated to equal approximately USD 5.2 million (the “Sale of Assets”) to KemPharm following the adoption of the restructuring proposal.

Orphazyme completes sale of substantially all of its assets and business activities to KemPharm

Read more

Restructuring proposal adopted by creditors

May 30, 2022

Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces that today an in-court meeting was held where the restructuring proposal as published by the Company through company announcement no. 26/2022 on May 18, 2022, was approved by the Company’s creditors and affirmed by the Danish Maritime and Commercial High Court in accordance with sections 13 d and 13 e of the Danish Insolvency Act.

Restructuring proposal adopted by creditors

Read more

Changes to the Board of Directors

May 23, 2022

Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, has previously announced its entry into an agreement with KemPharm Denmark A/S to sell substantially all of its assets and business activities (please see company announcement no. 24/2022) and submission of the restructuring proposal to the Danish Maritime and Commercial High Court (the “Court”) and the Company’s known creditors (please see company announcement no. 26/2022). 

Changes to the Board of Directors

Read more

Restructuring Proposal

May 18, 2022

Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces that the enclosed restructuring proposal (the “Restructuring Proposal”) will be submitted to the Danish Maritime and Commercial High Court (the “Court”) and be sent to the Company’s known creditors following the agreement with KemPharm Denmark A/S to sell substantially all of its assets and business activities (the “Assets”), which is conditional upon the approval by the creditors and the affirmation of the Restructuring Proposal by the Court (please see company announcement no. 24/2022).

Restructuring Proposal

Restructuring proposal including appendices

Read more

Updated Financial Calendar for 2022

May 16, 2022

Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces an update to the Company’s financial calendar for the remainder of 2022 following the signing of a binding agreement with KemPharm, Inc. for sale of substantially all of the company’s assets and business activities during the Company’s in-court restructuring proceedings (see company announcement no. 24/2022).

Updated Financial Calendar for 2022

Read more

Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.

May 15, 2022

Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC), announces today that it has signed an agreement to sell substantially all of the Company’s assets and business activities to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm Inc. (KMPH: NASDAQ, NY). KemPharm is a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system diseases.

Orphazyme AS under In Court Restructuring to sell substantially all of its assets and business activities to KemPharm Inc 0

Read more

Orphazyme announces update on in-court restructuring proceedings

Apr 29, 2022

Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces an update to the in-court restructuring proceedings of the Company (please see company announcement no. 10/2022 and 11/2022).

Orphazyme announces update on in court restructuring proceedings

Read more

1 ... 3 4 5 6 7 ... 23